<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429973</url>
  </required_header>
  <id_info>
    <org_study_id>EC11-444 OSTEOSARC</org_study_id>
    <nct_id>NCT02429973</nct_id>
  </id_info>
  <brief_title>Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma</brief_title>
  <acronym>GEIS-29</acronym>
  <official_title>Multicenter and Prospective Phase II Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Broto, Javier Martín, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Broto, Javier Martín, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter and prospective phase II trial with gemcitabine and rapamycin in second line of&#xD;
      metastatic osteosarcoma. The study includes 6 cycles of the combination gemcitabine+rapamycin&#xD;
      in metastatic or unresectable osteosarcoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial seeks to analyze progression free survival (PFS), measured as PFS rate at 4 months,&#xD;
      in patients with metastatic osteosarcoma who have previously received the most active drugs&#xD;
      in this disease (methotrexate, cisplatin, adriamycin and ifosfamide). The treatment schedule&#xD;
      consists of a maximum of 6 cycles of 3 weeks of gemcitabine+rapamycin. Gemcitabine is given&#xD;
      at 800 mg/m2 in days 1 and 8 in cycles of 21 days. Rapamycin is given at 5 mg per day during&#xD;
      treatment duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) rate</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response according to RECIST</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of gemcitabine plus rapamycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine plus rapamycin</intervention_name>
    <description>Gemcitabine and rapamycin given in combination</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed before any trial test&#xD;
&#xD;
          -  Age equal or less than 80 years&#xD;
&#xD;
          -  Histological diagnosis of high-grade, metastatic or unresectable osteosarcoma in&#xD;
             progression&#xD;
&#xD;
          -  Previous treatment with drugs used in first line: methotrexate, adriamycin, platinum&#xD;
&#xD;
          -  Measurable disease, acoording to RECIST criteria&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have been irradiated on target lesions&#xD;
&#xD;
          -  ECOG &gt;2&#xD;
&#xD;
          -  Bilirubin levels over normal values. Creatinine over 1.6 mg/dL&#xD;
&#xD;
          -  History of other cancers except basal cell cancer or cervical cancer adequately&#xD;
             treated&#xD;
&#xD;
          -  Serious cardiovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Martin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virgen del Rocío Hospital</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

